The company’s very first commercial product, Truforma is a shoebox-sized point-of-care diagnostic tool for veterinary offices. In January, Carole Baskin of Tiger King fame was paid $299 by a fan to mention Zomedia on Cameo. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Zomedica is an animal health company that develops technology to improve the care of companion animals. It attempted a reverse stock split that failed, then released more shares when its stock shot up in value – a move that kicked off the current drop in ZOM stock prices. Tags. Zomedica appears to be in solid financial shape while it waits for the launch of Truforma to shift into high gear. Readers are cautioned that this list of risk factors should not be construed as exhaustive. Unauthorized distribution, transmission or republication strictly prohibited. The big news for Zomedica and any investors who have interest in this company as a long-term holding is Truforma. About ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. The pandemic-fueled pet boom is only going to raise that. 365 Bloor Street East, Toronto, Ontario, M4W 3L4. Sound like something you’d like to wade into? Beyond TRUFORMA™ , Zomedica’s pipeline of additional diagnostic and pharmaceutical products is also expected to deliver revenue-generating rewards. Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. If you don't see it please check your junk folder. After Earnings, the Battle Over Nio Stock Is All About Valuation. Investor Relations Contact: PCG Advisory Kirin Smith, Presidentksmith@pcgadvisory.com+1 646.823.8656. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica is a winner with its pet lab product and cash balance. It allows veterinarians to conduct tests onsite for cats and dogs. Zomedica took advantage of the run up in price to issue more shares, bringing $173.5 million in cash. The company’s claim to fame is its TRUFORMA diagnostics platform. Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system — with returns rivaling even Warren Buffett. We ask you to keep your comments relevant and respectful. In further news, the first group of direct Zomedica field personnel have completed their training in anticipation of the commercial release of TRUFORMA. Robert Cohen, Chief Executive Officer of Zomedica, commented: “As you know, since our fundraising round in July of 2020, we have wanted to rationalize the Preferred Shares. But, what’s with this recent drop in ZOM? March may seem like a long way off. In his latest feat, Louis discovered the “Master Key” to profiting from the biggest tech revolution of this (or any) generation. About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. However, it’s just around the corner, and it will be a significant month for Zomedica… Shares of Zomedica Corp. (ZOM) soared up to 50% in the premarket following the announcement of the expected commercialization date for its TRUFORMA… We encountered an issue signing you up. Readers are cautioned not to place undue reliance on forward-looking information. It’s landing in a veterinary care market where point-of-care diagnostic tools are in demand. Copyright © 2021 InvestorPlace Media, LLC. Being able to conduct the test themselves gives faster results, allowing for a quicker start of treatment. Naturally the market didn’t like that move, and ZOM stock has slipped about 30% since the deal closed. Zomedica is a veterinary testing and pharmaceutical company with a much-anticipated product: Truforma. Zomedica Completes Verification of its TRUFORMA™ Point-of-Care Diagnostic Platform and the First Assay, Canine total T4 Meets Major Development … If the investigative studies continue as intended, Zomedica will remain on pace to deliver multiple products to market during 2021 and position the company as an integral provider of potentially industry-changing diagnostic tools. Of course, that’s exceptionally bullish for ZOM stock. Zomedica intends to launch Truforma at the end of March, but that won't happen if the company can't produce successful validation data. Stephanie Morley, President & Chief Medical Officer of Zomedica, commented: "Setting the date for the availability of TRUFORMA is the culmination of a dream for … That has been the ZOM stock story in 2021. This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Zomedica slowly but steadily made up most of that loss in the next few days, ending the week up more than 15%. 1125 N. Charles St, Baltimore, MD 21201. Press Release Zomedica CEO Issues Shareholder Letter as TRUFORMA(TM) Nears Commercialization Published: Jan. 18, 2021 at 11:14 a.m. Zom. Sales representatives of Miller Veterinary Supply, Zomedica’s distribution partner, also have completed their initial training program. Truforma's patent-protected system uses bulk acoustic wave (BAW) technology, which is said to be precise and reliable. The exchange of the Preferred Shares for common shares eliminates this potential detrimental effect, results in a “clean” balance sheet for the Company, and removes what was, in our opinion, a potential overhang on the common shareholders. We are appreciative that Wickfield Bridge Fund LLC, holders of the Preferred Shares, agreed with us that the elimination of the punitive terms of the Preferred Shares was in the best interests of all shareholders.”. Six months ago, 15 million shares would trade hands on a good day. This is another case of hype causing a dramatic spike in value. An attempted reverse stock split was rejected by shareholders. Truforma. PostPandemic: How COVID-19 is reshaping Canada, Zomedica Retires Preferred Shares TRUFORMA® Progressing Toward Commercialization. Zomedica expects that the verification study will demonstrate that the performance of the TRUFORMA™ platform can deliver sensitivity and specificity equal to or … At this stage, tests are available for thyroid and adrenal issues, but more are coming, including tests for gastrointestinal conditions – currently the most common insurance claim for dog owners. ZOM stock is worth as much as $3.61 following its Truforma product launch. TRUFORMA is Zomedica’s first product, planned for sales to start on March 30, 2021. Zomedica is bringing innovative, non-optical, fluorescence-free technology to the veterinary world — and your clinic — with TRUFORMA. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. 2021 InvestorPlace Media, LLC. Going forward, the only dog posts that are allowed is real pics of dogs being tested using the TRUFORMA® platform. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. This section was produced by a partner’s editorial department. However, things aren’t quite that simple when it comes to Zomedica. Investors continued to bid up Zomedica… In 2021, things really began to spin. 7 Robinhood Stocks To Buy for Your Penny Stocks Portfolio, As the Bubble Deflates, Churchill Capital IV Stock Will Get Interesting. Heck, the stock was even flogged on Cameo by a celebrity. The recent dip in Zomedica Corp.’s (ZOM) stock is a big opportunity for investors to jump in and buy the stock at a relatively lower price. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Nasdaq Zomedica's product is Truforma, which is an analyzer device intended for veterinarians' offices. There was an error, please provide a valid email address. Still, Zomedica has a compelling growth opportunity. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc. A welcome email is on its way. This section is Partnership Content presented by GlobeNewswire. Last November, ZOM was a penny stock facing the prospect of delisting. Postmedia was not given the opportunity to put restrictions on the content but has reviewed it prior to publication. Zomedica Corp (NYSE:ZOM) has been an interesting case study in the power of hype – Reddit, Robinhood and celebrity endorsements (even accidental ones) – to propel a stock to stratospheric levels. Zomedica Pharmaceuticals Corp. Press Release. Zomedica believes that the TRUFORMA platform represents the first use of BAW technology in disorder and disease-state diagnostics. That means there's still … The company has completed its launch team and is set to commercialize its first product for dogs and cats. Please try again. Reader AdvisoryExcept for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. For more information, visit www.ZOMEDICA.com. Especially not a random dog you got from google images. The Michigan-based company has no revenue. In further news, the first group of direct Zomedica field personnel have completed their training in anticipation of the commercial release of TRUFORMA. But does the prospect of finally generating revenue justify a 2,500% surge in ZOM stock price in four months? Sales representatives of Miller Veterinary Supply, Zomedica’s distribution partner, also have completed their initial training program. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. The big news for Zomedica and any investors who have interest in this company as a long-term holding is Truforma. Zomedica developed and implemented the training program to deliver a transformational learning program to its sales team through a defined process of providing a well-defined strategy, comprehensive disease state knowledge, and a clear understanding of the market and veterinary practice needs. Zomedica is an animal health company that develops technology to improve the care of companion animals. I would argue that it does not. It’s definitely worth checking back in to see how the company is doing once Truforma has hit the market, but for now its stock is just too volatile for my taste. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop a distribution network and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. In other words, if the company’s pending Truforma launch is such a hit that Zomedica gobbled up every dollar of possible revenue three years from … TRUFORMA® Progressing Toward Commercialization . Zomedica’s TRUFORMA platform represents the cost- and time-efficient future of veterinary diagnostics. The fallouts from that hype have included extreme volatility in ZOM stock. Gains of 41% one day, followed immediately by a drop of 14% the next session. Zomedica is on the verge of developing certain assays that might be the first ever available in veterinary medicine. Therefore, my pick is Zomedica. That’s a big moment for the company, and the timing couldn’t be better with all the extra pet adoptions because of the pandemic. But Truforma also serves a dramatically smaller customer base. Once Truforma is released, it … Effective March 7, 2021, Zomedica completed the exchange of all 12 of its outstanding Series 1 Preferred Shares, stated value $1.0 million per share, (the “Preferred Shares”) for 24,719,101 common shares of the Company, equivalent to $44 million based on a $1.78 per share closing price of the common shares on March 5, 2021. Liquid reagents come preloaded inside a disposable cartridge. Truforma goes on sale starting March 30. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition. The bottom line on Zomedica – like so many under-the-radar companies of late – is that it caught the attention of the Reddit/Robinhood investing crowd. Zomedica Corp. (ZOM) has been updating regarding the highly anticipated launch of TRUFORMA. TRUFORMA is … For historical reasons, although the Company received $12 million in exchange for the Preferred Shares, the Preferred Shares were entitled to a $108 million liquidation preference and a 9% royalty on the net sales of Zomedica and its affiliates. Copyright © Yes, the company is about to launch Truforma, its first product. Visit our Community Guidelines for more information and details on how to adjust your email settings. quotes delayed at least 15 minutes, all others at least 20 minutes. ANN ARBOR, Mich., March 08, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a … With chatter ramping up on Reddit, ZOM put together another big surge in February, gaining 137% over three sessions. Americans were already spending a fortune on pet health care ($29.3 billion in the vet office in 2019). BAW technology, also used in cell phones and in the world’s most advanced radar and communications systems, is an extremely reliable and precise technology.